How can Ehlers‑Danlos syndrome be definitively diagnosed in an elderly patient?

Definitive Diagnosis of Ehlers-Danlos Syndrome in Elderly Patients

The definitive diagnosis of hypermobile Ehlers-Danlos syndrome (hEDS)—the most common subtype—requires meeting all three 2017 international consensus criteria: (1) generalized joint hypermobility using age-adjusted Beighton scores (≥4/9 for patients ≥50 years), (2) presence of at least two features of a connective tissue disorder plus systemic manifestations, and (3) exclusion of alternative diagnoses through genetic testing and clinical evaluation. 1

Age-Adjusted Diagnostic Approach for Elderly Patients

Criterion 1: Generalized Joint Hypermobility Assessment

• Use the Beighton scoring system with age-appropriate cutoffs: ≥4/9 points for patients 50 years and older (compared to 5/9 for younger adults) 1
• The Beighton score evaluates: bilateral 5th finger hyperextension >90°, thumb-to-forearm apposition, elbow hyperextension >10°, knee hyperextension >10°, and forward trunk flexion with palms flat on floor 1
• Critical caveat: Joint hypermobility may decrease with age, making diagnosis in elderly patients more challenging if they were not evaluated earlier in life 2

Criterion 2: Systemic Manifestations

Require at least two of the following features 1:

• Soft, velvety, or hyperelastic skin
• Unexplained striae or atrophic scarring
• Chronic musculoskeletal pain (often present for decades)
• Positive family history of hEDS
• Additional systemic features including recurrent joint dislocations, chronic fatigue, or gastrointestinal symptoms 1

Criterion 3: Exclusion of Alternative Diagnoses—The Most Critical Step

Genetic testing is essential and clinically actionable, despite hEDS having no identified genetic marker. 3 This criterion excludes other EDS subtypes and mimicking conditions.

Mandatory Genetic Testing Panel

• Test for the 12 genetically-defined EDS subtypes using next-generation sequencing panels covering: COL5A1/2, COL3A1 (vascular EDS), COL1A1/2, TGFBR1/2, SMAD3, FBN1, and other collagen/aortopathy genes 3, 4
• 26.4% of patients meeting clinical hEDS criteria had alternative genetic diagnoses identified that required distinct management strategies 3
• Genetic testing can identify clinically actionable variants in aortopathy genes requiring cardiovascular surveillance 4

Why This Matters in Elderly Patients

• Older adults often present with prolonged diagnostic delays and multimorbidity that may mask underlying connective tissue disorders 2
• Symptom progression is heterogeneous and unpredictable across the lifespan 2
• Vascular EDS (caused by COL3A1 mutations) carries significant mortality risk and requires specific management—this must be excluded 5, 4

Common Diagnostic Pitfalls in Elderly Patients

Pitfall 1: Assuming Joint Stiffness Rules Out hEDS

• Joint hypermobility may diminish with age due to osteoarthritis and soft tissue changes 2
• Focus on historical evidence: Ask about childhood/young adult joint hypermobility, recurrent dislocations, or "double-jointedness" 2

Pitfall 2: Attributing All Symptoms to "Normal Aging"

• Chronic widespread pain, gastrointestinal dysfunction (98% meet DGBI criteria), and fatigue are core features, not just aging 1
• Consider hEDS/HSD when elderly patients present with unexplained multisystemic symptoms including orthostatic intolerance, mast cell activation symptoms, or treatment-refractory GI complaints 1

Pitfall 3: Skipping Genetic Testing

• Without genetic testing, you cannot definitively diagnose hEDS because you haven't excluded the 12 other EDS subtypes 3
• This is not optional—it changes management in over one-quarter of cases 3

Associated Conditions Requiring Targeted Testing

Do not universally screen all suspected hEDS patients, but test when clinically indicated 1:

Postural Orthostatic Tachycardia Syndrome (POTS)

• Test if patient reports: lightheadedness upon standing, palpitations, exercise intolerance
• Diagnostic criteria: heart rate increase ≥30 bpm within 10 minutes of standing without orthostatic hypotension 1

Mast Cell Activation Syndrome (MCAS)

• Test if patient has: flushing, urticaria, unexplained anaphylaxis, multisystem symptoms triggered by foods/temperature/stress
• Requires symptoms in ≥2 organ systems plus laboratory evidence of mast cell mediators 1

Clinical Algorithm Summary

1. Assess age-adjusted Beighton score (≥4/9 for age ≥50 years) and document historical joint hypermobility 1
2. Identify ≥2 systemic connective tissue features plus family history or additional manifestations 1
3. Order comprehensive genetic testing panel for all 12 genetically-defined EDS subtypes—this is mandatory, not optional 3, 4
4. Clinically evaluate for POTS/MCAS only if symptoms suggest these conditions 1
5. If genetic testing is negative and all three criteria are met, diagnose hEDS; otherwise, classify as hypermobility spectrum disorder (HSD) 1, 6

The 2017 criteria have been criticized as overly stringent, potentially missing patients who would benefit from diagnosis and management 6. However, they remain the current diagnostic standard and emphasize that genetic exclusion is non-negotiable for definitive diagnosis 3.